6505--ME/ New Pluvicto Theronastic Therapy Radiopharmaceuticals/STL(VA-26-00053903) 657-26-4-1642-0063
Award Notice Posted
- Solicitation number
- 36C25526N0394
- Agency
-
Veterans Integrated Service Network 15
Veterans Health Administration, Department of Veterans Affairs
- Awarded
- to Novartis Pharmaceuticals Corporation
- Set-aside
- No set-aside
Opportunity facts
- Contract number
- 36F79720D018036C25526N0394 Federal contract award
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
The Department of Veterans Affairs Network Contracting Office 15 awarded a Federal Supply Schedule order to Novartis Pharmaceuticals Corporation on August 5, 2026, for 26 units of PLUVICTO (Lutetium Lu 177 vipivotide tetraxetan) totaling $891,650.76.
The ordering period runs August 5, 2026 through February 5, 2027. Place of performance is VA St. Louis Health Care System John J. Cochran Veterans Hospital, St. Louis, MO. The award was made under unrestricted competition (no set-aside). PLUVICTO is a proprietary radiopharmaceutical indicated for adult patients with PSMA-positive metastatic castration-resistant prostate cancer who have received prior androgen receptor pathway inhibition and taxane-based chemotherapy. Unit price is $34,294.26. The award is issued under FSS Contract 36F79720D0180, Order Number 36C25526N0394.
Notice text
Ordering Activity / Contracting Office
Department of Veterans Affairs
Network Contracting Office (NCO 15)
3450 S 4th Street Trafficway
Leavenworth, KS 66048
Contract / Order Information
FSS Contract Number: 36F79720D0180
Order Number: 36C25526N0394
Requisition / PO Number: 657-C60305
Effective Date of Award: August 5, 2026Ordering Period: August 5, 2026 through February 5, 2027
Method of Solicitation: FSS order under SF 1449, commercial products and commercial services
Awardee (Contractor)
Novartis Pharmaceuticals Corporation
59 Route 10
East Hanover, NJ 07936
UEI: NG61ZA8TADW3 (as shown on the SF 1449).
Primary Contractor POC:
Yisell Rodriguez, 201 602 5055, yisell.rodriquez@novartis.com.
Place of Delivery / Performance
VA St. Louis Health Care System
John J. Cochran Veterans Hospital
915 North Grand Boulevard
St. Louis, MO 63106
Description of Supplies/Services
This award provides one proprietary radiopharmaceutical agent, PLUVICTO (Lutetium Lu 177 vipivotide tetraxetan), NDC 69488 0010 6, for use by Nuclear Medicine at VA St. Louis Health Care System.
PLUVICTO is indicated for adult patients with PSMA positive metastatic castration resistant prostate cancer who have been treated with androgen receptor pathway inhibition and taxane based chemotherapy.
The period of performance supports diagnostic and therapeutic use of this radiopharmaceutical in accordance with the Statement of Work included in the SF 1449.
Line Item and Pricing
CLIN 0001: PLUVICTO Lutetium Lu 177 vipivotide tetraxetan, NDC 69488 0010 6.
Quantity: 26 Each.
Unit Price: 34,294.26.
Extended Amount: 891,650.76.
Total Award Amount: 891,650.76.
Funding / Accounting Data
As shown on SF 1449:
657 26 4 1642 0063 / 657 3660 / 160 1642 822900 2580 / 0100L00H6 (Accounting and Appropriation Data).
Invoice and Payment Instructions
Invoices shall be submitted monthly in arrears and must reference PO number 657 C60305 and Order number 36C25526N0394.
All invoices shall be submitted electronically in accordance with VAAR 852.232 72, via the VA Financial Services Center e-invoicing system (Austin, TX).
Payment will be made by: Department of Veterans Affairs Financial Services Center, Austin, TX (see SF 1449 Block 18a and Continuation Page for full details).
Contract Administration / Points of Contact
Contracting Officer:
Michael P. Murphy
Department of Veterans Affairs
Network Contracting Office (NCO 15)
3450 S 4th Street Trafficway, Leavenworth, KS 66048
Email: michael.murphy7@va.gov
Phone: 913 946 1970
Facility Point of Contact (Pluvicto):
Mark Lauridsen
VA St. Louis Health Care System
Email: mark.lauridsen@va.gov
Phone: 314 652 4100 ext. 66522
The Contracting Officer retains sole authority to approve changes or modifications affecting price, quantity, or quality of performance under this contract.
The Contracting Officer s Representative (COR) will be designated separately in accordance with VAAR 852.270 1 and will be responsible for technical and administrative oversight.
Special Terms and Conditions
This order is subject to the terms and conditions of FSS Contract 36F79720D0180 and all clauses incorporated by reference on SF 1449, including VAAR 852.247 71 (Delivery Location), VAAR 852.232 72 (Electronic Submission of Payment Requests), VAAR 852.203 70 (Commercial Advertising), VAAR 852.242 71 (Administrative Contracting Officer), and VAAR 852.246 71 (Rejected Goods).
The VA St. Louis Health Care System s business hours and applicable federal holidays are as set forth in the Statement of Work, and contract performance monitoring will be conducted in accordance with VA quality assurance procedures described therein. Awarded contract 36F79720D018036C25526N0394 to Novartis Pharmaceuticals Corporation for 891650.00 on 2026-08-05.
Files
| File | Type | Posted |
|---|---|---|
| 36F79720D0180 36C25526N0394_1.docx | DOCX document |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity